Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
暂无分享,去创建一个
M. Berger | C. Iacobuzio-Donahue | S. Leach | K. Offit | J. Vijai | M. Robson | G. Abou-Alfa | A. Zehir | E. Jordan | Z. Stadler | M. Lowery | A. Varghese | D. Klimstra | D. Hyman | P. Allen | M. Capanu | E. Salo-Mullen | Semanti Mukherjee | Vignesh Ravichandran | Y. Kemel | D. Mandelker | A. Arnold | D. Kelsen | G. Askan | W. Wong | Kenneth H. Yu | E. O’Reilly | C. Tjan | Christina M. Covington | R. Brenner | Jonathan W Lee | E. Kaufmann | Hannah Maynard | Jonathan W. Lee
[1] Song-Cheol Kim,et al. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing , 2018, Investigational New Drugs.
[2] P. Kantoff,et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.
[3] Masaya Suenaga,et al. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] N. Schultz,et al. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype , 2017, Clinical Cancer Research.
[5] Kenneth H. Yu,et al. Pancreas adenocarcinoma: novel therapeutics. , 2017, Chinese clinical oncology.
[6] Richard J. Wenstrup,et al. PREVALENCE OF GERMLINE MUTATIONS IN CANCER GENES AMONG PANCREATIC CANCER PATIENTS WITH POSITIVE FAMILY HISTORY , 2017, Genetics in Medicine.
[7] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[8] V. Seshan,et al. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.
[9] J. Potash,et al. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. , 2016, Cancer discovery.
[10] K. Offit,et al. Identification of germline genetic mutations in patients with pancreatic cancer , 2015, Cancer.
[11] H. Kindler,et al. POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (gBRCAm) who have not progressed following first-line chemotherapy. , 2015 .
[12] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[13] David M. Thomas,et al. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial , 2015, Clinical Cancer Research.
[14] G. Petersen,et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. , 2015, Gastroenterology.
[15] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[16] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Bennett,et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment , 2014, Genetics in Medicine.
[18] Benjamin D. Smith,et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.
[19] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[20] W. Chung,et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. , 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[22] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[23] S. Gruber,et al. Genetic/familial high-risk assessment: breast and ovarian. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[24] Alan Ashworth,et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.
[25] D. Zwijnenburg,et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.
[26] M. Jasin,et al. BRCA2 is required for homology-directed repair of chromosomal breaks. , 2001, Molecular cell.
[27] C. Moskaluk,et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.
[28] Laura H. Tang,et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. , 2018, European journal of cancer.
[29] E. Knudsen,et al. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. , 2016, Gastroenterology.
[30] K. Behrns. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .